RxDoctor Payments Data

Roger Kasendorf, DO

Pain Medicine · la Jolla, CANPI 1356371884

Payments from drug & device makers

$32,390in general payments, 2019–2025

Across 648 payments — averaging $49.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$14K
  • Biohaven Pharmaceuticals, Inc.$4K
  • Biohaven Pharmaceutical Holding Company Ltd.$3K
  • West Therapeutics Development, LLC$3K
  • Collegium Pharmaceutical, Inc.$1K
  • AbbVie$1K
  • plus $7K from 47 others

What the payments were for

  • Consulting fees$1250%
  • Speaking & faculty fees$16,47051%
  • Travel & lodging$5,33116%
  • Food & beverage$10,23232%
  • Education$2161%
  • Entertainment$160%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,390 in reported general payments places this provider in the 90th percentile of 840 pain medicine providers in California.

See all pain medicine providers in California

Medicare billing

Part B allowed, 2024
$364,330
Medicare patients
224
Services billed
9,822

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate17$26,400
Buprenorphine67$17,324
QuliptaAtogepant13$16,025
OxycontinOxycodone Hcl12$9,199
Oxymorphone Hcl ErOxymorphone Hcl11$7,971
Fentanyl51$7,427
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen195$6,207
ButransBuprenorphine12$5,825
Oxycodone Hcl165$5,023
Morphine Sulfate24$3,794
Doxepin Hcl25$3,718
Lidocaine13$2,268
Morphine Sulfate ErMorphine Sulfate66$1,931
Gabapentin89$1,648
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl15$1,327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$1,325$26,40017 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate, Buprenorphine-Naloxone$93$22,445106 claims
AbbVieQulipta$1,186$16,02513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 840 pain medicine providers in California.

Other pain medicine in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →